On May 20, 2020 OBI Pharma reported that Taiwan Hao Ding (TPEx: 4174) will publish a paper at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) online annual meeting from 29 to 31 this month, explaining its research and development products, including the new breast cancer drug Adagloxad Simolenin (OBI) that has entered the third phase of clinical trials -822), Globo H antibody small molecule drug complex OBI-999 and AKR1C3 small molecule chemotherapy prodrug OBI-3424 progress (Press release, OBI Pharma, MAY 20, 2020, View Source [SID1234561054]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Due to the epidemic situation, ASCO (Free ASCO Whitepaper) 2020, a globally-focused cancer medical conference, was changed online this year. Hao Ding is currently the leader in the field of immunotumor therapy with the Globo series of antigens as the target. It will present the clinical research data of the first cancer breakthrough new drugs for different tumors against Globo H and AKR1C3 antigens.
These studies will be introduced by the main researchers of Hao Ding at the meeting to introduce the first anti-Globo H cancer vaccine Adagloxad Simolenin (OBI-822) and the antibody small molecule complex OBI-999 and the chemical small molecule prodrug OBI-3424 for AKR1C3.
Dr. Tillman Pearce, Chief Medical Officer of Hao Ding, pointed out that in order to meet the high medical needs of effective treatments, Hao Ding is honored to present the first breakthrough medical treatments including ABI-822, OBI-999 And OBI-3424 test progress. He sincerely hopes that the future development of these anti-Globo H and AKR1C3 targeted therapies can provide potential therapeutic benefits for cancer patients.
Hao Ding ASCO (Free ASCO Whitepaper) published online three papers as follows, 5 Yue 29 Ri will also be published on the official website of Taiwan Ding Hao www.obipharma.com
1. Abstract: TPS599 / Poster: 91
Title:
Phase 3, randomized, double-blind, placebo-controlled study of adagloxad simolenin (OBI-822) clinical trial to evaluate OBI-822/821 against high-risk early-stage triple negative breast cancer (TNBC) Patient’s treatment effectiveness and safety. Speaker : Hope S. Rugo, Professor of Medicine, San Francisco Helen Diller Family Comprehensive Cancer Center, FASCO University, San Francisco, California
, USA
Report Group: Breast Cancer-Local/Regional/Assisted
Report Time: 29/05/2020 (Friday) 8:00 AM am – 11:00 am (Eastern Coast Time)
link: View Source
2. Abstract: TPS3657 / Poster: 387
Title: OBI-999
A phase I/II, clinical phase I/II open trial, dose escalation and population expansion test to evaluate the safety of OBI-999 in patients with advanced solid tumors , Pharmacokinetics and therapeutic activity.
Report categories: Development Therapy – molecular target drugs and tumor biology
Speaker: MD Anderson Cancer Center professor of medicine at the University of Texas Apostolia Maria Tsimberidou.
Report Date: 29/05/2020 (Friday) morning 8:00 am – 11:00 am (Eastern Coast Time)
link: View Source
3. Abstract: TPS3658 / Poster: 388
Title: OBI-3424
OBI-3424 is a chemical prodrug that selectively acts on AKR1C3 aldehyde and ketone reductase and is currently undergoing Phase I/II clinical trials to include hepatocellular carcinoma (HCC) Patients with advanced cancer of castration-resistant prostate cancer (CRPC) were the subjects.
Report categories: Development Therapy – molecular target drugs and tumor biology
Speaker: MD Anderson Cancer Center professor of medicine at the University of Texas Apostolia Maria Tsimberidou.
Report Date: 29/05/2020 (Friday) morning 8:00 am – 11:00 am (Eastern Coast Time)
link: View Source